| P/E (FY) | — | Sales (TTM) | $71.6M |
| Earnings (TTM) | -$294.6M | ROE | −94.82% |
| Net Margin | −412.95% | ROIC | −205.50% |
| Debt / Equity | 0.06 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Kura Oncology is a clinical-stage biopharmaceutical company developing medicines for cancer treatment. Its first commercial product, KOMZIFTI (ziftomenib), is an oral small molecule menin inhibitor. The pipeline also includes darlifarnib, evaluated in the Phase 1 FIT-001 trial in combination with targeted therapies for solid tumors, and KO-7246, a next-generation menin inhibitor. The company is headquartered in San Diego, California.
| Market Cap | $826.5M | Trading Days | 2693 |
| 52W High | 12.49 |
| 52W Low | 5.45 |
| % Off High | −25.46% |
| YTD | −10.39% | 1Y | 50.28% |
| 3Y | −6.62% | 5Y | −50.95% |
| 10Y | 135.10% | Since incept. (ann.) | 1.61% |
License And Collaboration Revenue 97% · Product 3%
| Ann. Volatility (1Y) | 61.36% | Ann. Volatility (3Y) | 64.21% |
| Sharpe (1Y) | 0.97 | Sharpe (3Y) | 0.29 |
| Max Drawdown (1Y) | −39.04% | Max Drawdown (3Y) | −76.46% |
| Beta (3Y, vs SPY) | 1.35 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CMMB | Chemomab Therapeutics Ltd. | $822.8M | 79.4 |
| ESPR | Esperion Therapeutics, Inc. | $818.6M | — |
| OMER | OMEROS CORP | $816.4M | — |
| TBPH | Theravance Biopharma, Inc. | $870.7M | 8.2 |
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| ANNX | Annexon, Inc. | $770.9M | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $888.5M | 9.9 |
| CYRX | Cryoport, Inc. | $764.6M | 10.8 |
| JANX | Janux Therapeutics, Inc. | $914.8M | — |
| ACRS | Aclaris Therapeutics, Inc. | $744.4M | — |
| DSGN | Design Therapeutics, Inc. | $741.4M | — |
| PHAT |
| Phathom Pharmaceuticals, Inc. |
| $930.0M |
| — |
